๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Selegiline in the treatment of Parkinson's disease: its impact on orthostatic hypotension

โœ Scribed by K.F. Bhattacharya; S. Nouri; C.W. Olanow; M.D. Yahr; H. Kaufmann

Book ID
117751831
Publisher
Elsevier Science
Year
2003
Tongue
English
Weight
94 KB
Volume
9
Category
Article
ISSN
1353-8020

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Nonpharmacological treatment, fludrocort
Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease
โœ Kerrie L. Schoffer; Robert D. Henderson; Karen O'Maley; John D. O'Sullivan ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 94 KB

## Abstract There is limited evidence for the treatment of orthostatic hypotension in idiopathic Parkinson's disease. The objective of this study was to determine the efficacy of three treatments (nonpharmacological therapy, fludrocortisone, and domperidone). Phase I assessed the compliance, safety

Selegiline ? An overview of its role in
Selegiline ? An overview of its role in the treatment of Parkinson's disease
โœ Wessel, K. ;Szelenyi, I. ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› Springer-Verlag ๐ŸŒ English โš– 389 KB

Selegiline (10 mg per day) selectively inhibits monoamine oxidase type B and thus thwarts the metabolism of dopamine by this enzyme. Selegiline has been used in the therapy of Parkinson's disease since 1986. It enhances the efficacy of levodopa, allows a reduction of the levodopa dose, and improves